Waldenström Macroglobulinemia

>

Latest News

Image of a pill split in half with graphics of circles in the middle, symbolizing technology.
FDA Approves Easier-to-Swallow Imbruvica Formulation

February 29th 2024

An oral suspension formula of Imbruvica received the green light from the Food and Drug Administration to be used in all approved indications.

Image of lymphoma
Novel Drug Shows 100% Disease Control Rate in WM

January 9th 2024

FDA Lifts Partial Hold on Trial Investigating Emavusertib in Lymphoma
FDA Lifts Partial Hold on Trial Investigating Emavusertib in Lymphoma

August 19th 2022

FDA Grants Orphan Drug Designation to Novel CAR-T Cell Therapy to Treat Waldenstrom Macroglobulinemia, a Rare Type of Cancer
FDA Grants Orphan Drug Designation to Novel CAR-T Cell Therapy to Treat Waldenstrom Macroglobulinemia, a Rare Type of Cancer

June 27th 2022

Brukinsa Continues to Outperform Imbruvica for MYD88-Mutant Waldenström Macroglobulinemia
Brukinsa Continues to Outperform Imbruvica for MYD88-Mutant Waldenström Macroglobulinemia

June 10th 2022

Podcasts
Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.

More News